[8] [9] HCT-116 10-100 μM / 24-72h apoptosis; caspase 2, 8 [10] SW480, SW620, HT-29 IC50 30 μM / 48h apoptosis; ERK, JNK, Akt [11] Colon DLD1 100 μM / 48h apoptosis; caspase 3 [12] cyclin-D1, -E, cdk 4, cyclin-D1/cdk4 kinase activity; p53, p21, and p27 (only LNCaP cells) LNCaP 1-50 M / 24h cell proliferation; apoptosis; caspase 3, 9; change in the ratio of Bax/Bcl-2; G0/G1 cell cycle arrest; PI3K, p-Akt, Bcl-2; Bax, Bak, Bid, and Bad [14] LNCaP, DU145 1-100 M / 24-72h apoptosis; MTA1/NuRD; p53, p21, Bax [15] LNCaP 1-25 μM / 24-72h G0/G1 cell cycle arrest; cdk inhibitor 1A and B [16] PC-3 cells 1-50 M / 24h XRT-induced apoptosis and proliferation inhibition; p15, p21, p53; cyclin-B, -D and cdk2; p-H2A.X [17] PC3, CWR22rv1 2.5-10 μM / 7-10 days IR-induced apoptosis and proliferation inhibition; G0/G1 and S cell cycle arrest; p27, p21, p53; caspase 3; p-Akt [23] [24] [25] [26] Huh-7 IC50=22.4 μM cell proliferation; G0/G1 cell cycle arrest; cyclin -A, -E and cdk 2; apoptosis; p53, p21/WAF1; p-ERK, p-p38; autophagy-related Atg5, Atg7, Atg9, and Atg12 proteins [27] SK-HEP-1 50-250 μM / 24-48h cell proliferation; apoptosis/caspase 3; ROS [28] Liver HepG2, Hep3B cell proliferation; G0/G1 cell cycle arrest (MCF-7); apoptosis; NHE-1 and NHE-3; uptake of NaCl; pH [36] [37] [38] [39] [40] [41] PC12 cells with oxygen-glucose deprivation Pretreatment, cotreatment and post-treatment 5-25 M / 6-24h ROS; GSH; HIF-; Caspase 3, Bax, Bcl-2 [22] Human neuroblastoma SH-SY5Y cells treated with paclitaxel 1 M
1-100 M / 24h
Cell survival; caspase 7 and PPAR activation [23] Organotypic hippocampal slice cultures with oxygen-glucose deprivation 10-50 M / 24h Cell survival; PI3K [24] Neuro2a cells/mouse dorsal root ganglia (DRG) sensory and cortical neuron cultures 10 M / 2-72h AMPK phosphorylation; ACC phosphorylation; Differentiation;
Mitochondrial biogenesis [25] 8-iso-PGF2 , 8-iso-prostaglandin-F2 ; ACC, acetyl-CoA carboxylase; AIF, apoptosis inducing factor; Akt, protein kinase B; -syn, alpha-synuclein; AMPK, adenosine monophosphate activated protein kinase; A , amyloid beta peptide; ATF1, activating transcription factor 1; Bax, Bcl2-associated X protein; Bcl-2, B-cell lymphoma 2; Casp3, caspase 3; COX-2, cyclooxigenase 2; CREB, cAMP response element-binding; GPx, glutathione peroxidase; GSH, glutathione; GSK-3 , glycogen synthase kinase 3beta; HIF-, hypoxia inducible factor; HO-1, heme oxygenase-1; IL-1 , interleukin 1-alpha; IL-1 , interleukin 1-beta; MAPKs, Mitogen-activated protein kinases; mPGES-1, membrane-associated PGE synthase-; mTOR, mammalian target of rapamycin; iNOS, inducible nitric oxide synthase; NFkB, nuclear factor kappa B; NO, nitric oxide; PGC-1 , peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGE2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PPAR, peroxisome proliferator-activated receptor; ROS, reactive oxygen species; SIRT1, sirtuin 1; SOD2, superoxide dismutase 2; TNF , tumour necrosis factor alpha; XO, xanthine oxidase. Effect is indicated by : reduction; : induction; p-: phosphorylate status. COX, cyclooxygenase; EA.hy 926, human umbilical vein cell line; EC, endothelial cells; eNOS, endothelial nitric oxide synthase; GCH1, GTP cyclohydrolase 1; GCLC, glutamatecysteine ligase catalytic subunit; GPx, glutathione peroxidase; GSH, glutathione; HASMC, human aortic smooth muscle cells; HBMEC, human brain microvascular endothelial cells, HCAEC, human coronary artery endothelial cells; HSVEC, human saphenous vein endothelial cell; HUVEC, human umbilical vein endothelial cells; HO-1, heme oxygenase-1; HSP, heat shock protein; ICAM-1, intercellular adhesion molecule 1; IL, interleukin; iNOS, inducible nitric oxide synthase; LB4, leukotriene B4; MCP, monocyte chemotactic protein; MMP, matrix metallopeptidase; MPO, myeloperoxidase; NADPH, nicotinamide adenine dinucleotide phosphate; NF-B, nuclear factor-B-binding; NO, nitric oxide; NOX, NADPH oxidase; NQO, NADPH: quinone oxidoreductase; Nrf, nuclear factor-E2-related factor; PGC, peroxisome proliferator-activated receptor-coactivator; PGE2, prostaglandin E2; ROS, reactive oxygen species; SGBS, human Simpson-Golabi-Behmel syndrome; SIRT1, sirtuin (silent mating type information regulation 2 homolog) 1; SOD, superoxide dismutase; Tfam, transcription factor A, mitochondrial; THP-1, human acute monocytic leukemia cell line; TNF, tumor necrosis factor; Trx, thioredoxin; U937, human macrophage cell line; VCAM-1, vascular cell adhesion protein 1; VEGF, vascular endothelial growth factor; , reduction; , induction. Supplementary Table 4 . Anti-aging effects of resveratrol in in vitro models. Supplementary Table 6 .
Supplementary

Cell Model Treatment Effects and Mechanisms Reference
Effects of exposure to resveratrol on animal models of cardiovascular disease. AMPK, AMP activated protein kinase; b.i.d., twice a day; bw, body weight; COX, cyclooxygenase; CRP, C-reactive protein; eNOS, endothelial nitric oxide synthase GCS-F, granulocyte colony-stimulating factor; IL, interleukin; iNOS, inducible nitric oxide synthase; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; MIG, MPO, myeloperoxidase; NF-B, nuclear factor-B-binding; NO, nitric oxide; ODC, colonic mucosal ornithine decarboxylase; PGE2, prostaglandyn E2; PGES-1, prostaglandin E synthase 1; sTNFRI, soluble Tumor Necrosis Factor Receptor I; TNF, tumor necrosis factor; , reduction; , induction; , no effect. Table 9 .
Supplementary
Neuroprotective effects of resveratrol in animal models.
Neurodegenerative
Model
Animal Model Treatment Effects and Mechanisms Reference
Parkinson Male Swiss mice exposed to paraquat/ maneb Male Sprague-Dawley rats 30 mg/kg (ip) / 7 days neurological deficit score; lactate release; glucose levels; ATP and EC levels; adesonine and inosine; hipoxanthine and xanthine; MDA, XO activity [11] Male and female C57BL/6 mice 1, 2.5, 5 mg/kg (iv) / administered 3 or 6h after arterial oclusion Infarct volume; IL-1 , TNF ; microglial activation (Iba1); ROS [12] xxiv Current Pharmaceutical Design, 2013, Vol. 19, No. 34 
Supplementary Tables
Male Sprague-Dawley rats 30 mg/kg (ip) / 7 days before ischemia Infarct volume; neurological deficit score; release Asp, Glu; GABA, Gly, Tau; PEA, Dser [13] Sprague-Dawley rats 10-100 mg/kg (ip) / 48 h before the induction of 8 min of asphyxial cardiac arrest normal neuron number; SIRT1 activity; UCP2; ADP/O ratio [14] Male Wistar rats 10 7 g/kg (iv) twice / 15 min pre-occlusion and at the time of reperfusion (2h postocclusion)
LPO, H2O2, G6-PD, LDH; PC, GSH; ATP, MT, HSP70; Apoptosis (cytochrome c release); DNA damage; Brain edema, infarct volume; Behavioral deficits [15] Male Balb/c mice 50 mg/kg/day (po) / 7 days Infarct volume; neurological deficit score; microvessels; MMP-2, VEGF [16] Male Long-Evans rats 0.01, 0.1, 1 μg/kg (iv) / after 1h MCA occlusion LDH plasma; NO plasma; iNOS; eNOS; infarct volume; MDA [17] Male Wistar rats 20 mg/kg (iv) / after ischemia hippocampal blood flow; NO; DHBA; SOD activity [18] Male Balb/C 50 mg/kg (po) / 7 days infarct area; MMP-9 expression & activity [19] Male New Zealand rabbits 1, 10 mg/kg / 30 min before SCI Tarlov score; neuronal damage; MDA; NO [20] Long-Evans rats Pretreatment /treatment groups 10 -6 , 10 -7 , 10 -8 , 10 -9 g/kg (iv) / 15 min before trauma infarct volume [21] Male C57/BL6 mice middleaged (18 months) 0.05% diet / 10 months MnSOD activity in muscle; H2O2, MDA; fast-twitch fiber contractile function [20] C57BWrn hel/ hel 0.04% diet / 9 months liver steatosis; liver sinusoidal endothelial defenestration; HOMA-IR index; DNA damage cardiac tissue; MDA (heart & liver); protein carbonylation; AMPK-; FASN expression; Glutation metabolism pathway; glycolisis/gluconeogenesis; piruvate metabolism; insulin signaling pathway [21] Caenorhabditis elegans 0.5-5 μM mean lifespan; maximum lifespan [22] F2 hybrid four-way cross mice (CB6F1 x C3D2F1 (C3H x DBA/2) of three age groups [25] Male C57Bl/6 mice 1 year old 15 mg/kg (po) / 12 months vascular density in brain; cognitive function; microvascular abnormalities [26] Senescence-accelerated mice (SAM) 0.2% (w/w) diet (po) / 13 weeks endurance capacity; body weight; adiponectine, Hb; insulin, TG, glucose, Serum and EDL TBARS; oxygen consumption; PGC-1 RNA; CYOX III, IV, MCAD [27] Male B6C3F(1) mice 1.25 mg/kg (po) / from 2 to 5 months of age Pdk4, Ucp3 [28] Male C57BL/6NIA 0.04% resveratrol (po) / beginning at one year of age motor coordination; vascular dysfunction ; aortic elasticity; cataract formation bone mineral density; functional decline; endothelial apoptosis; TNF , IL-1 , IL-6, ICAM-1, iNOS [29] Male C57BL/6 C3H/He F1 hybrid mice 50 mg /kg diet/ starting at 2 & 14 months of age until 30 months cardiac dysfunction; glucose levels; insuline resistence; PGC1-; F2isoprostanes in heart &brain [30] 8-iso-PGF2 , 8-iso-prostaglandin-F2 ; 8OHdG, 8-Oxo-2'-deoxyguanosine; AMPK, adenosine monophosphate activated protein kinase; C1qa, complement component 1q; C4, complement component 4; cAMP, cyclic adenosine monophosphate; CAT, catalase; CD4, cluster of differentiation 4; CD8, cluster of differentiation 8; CD25, cluster of differentiation 25; CD69, cluster of differentiation 69; Csprs component of Sp100-rs; Cxcl14, chemokine (C-X-C motif) ligand 14; CYOX, cytochrome c oxidase; dILp, insulin related peptide; EDL, extensor digitorium longus; FASN, fatty acid synthase; GPx, glutathione peroxidase; GstD1, glutathione S transferase D1; HSP68, heat shock protein 68; HOMA-IR, homeostatic model assessment-insulin resistance; ICAM-1, intercellular adhesion molecule 1; IFN-, interferon-gamma; IG, immunoglobulin; IL-2, interleukin 2; IL-4, interleukin 4; IL-5, interleukin 5; IL-6, interleukin 6; IL-10, interleukin 10; IL-1 , interleukin 1-beta; IL-6, interleukin 6; iNOS, inducible nitric oxide synthase; KLH, keyhole limpet hemocyanin; MCAD, medium-chain acyl-CoA dehydrogenase; MDA, malondialdehyde; MnSOD, manganese superoxide dismutase; NADPH, nicotinamide adenine dinucleotide phosphate; p53, tumour protein 53; Pah, phenylalanine hydroxylase; Pdk4, pyruvate dehydrogenase kinase isoform 4; PCC, acetyl-CoA carboxylase; PGC-, peroxisome proliferator-activated receptor gamma coactivator 1 beta; Prx2540-1, peroxiredoxin 2540-1; Prx6005, Peroxiredoxin 6005; ROS, reactive oxygen species; SA--Gal, senescence-associated beta-galactosidase; SIRT1, sirtuin 1; SKAP2, src kinase associated phosphoprotein 2; SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive substances; TG, tryglyceride; TNF , tumour necrosis factor alpha; Ucp3, mitochondrial uncoupling protein 3. Effect is indicated by : reduction; : induction; p-: phosphorylate status
